Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Noriyuki Kasahara, M.D., Ph.D.
Noriyuki Kasahara, M.D., Ph.D.


Professor, Department of Medicine, Department of Molecular and Medical Pharmacology
Director, CURE Vector Core and JCCC Vector Core Shared Resource
Member, JCCC Tumor Immunology Program Area

Contact Information:

(310) 825-7112

Scientific Interest(s):

Dr. Noriyuki Kasahara's research is focused on molecular therapeutics and gene transfer vector development.

Selected Cancer-Related Publications:

Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A, Jolson D, Amundson K, Buckley T, Lohse D, Lin A, Burrascano C, Ibanez C, Kasahara N, Gruber HE, Jolly DJ. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther. 2012 Sep;20(9):1689-98. Epub 2012 May 1

Collins SA, Hiraoka K, Inagaki A, Kasahara N, Tangney M. PET imaging for gene & cell therapy. Curr Gene Ther. 2012 Feb 1;12(1):20-32.

Hacke K, Szakmary A, Cuddihy AR, Rozengurt N, Lemp NA, Aubrecht J, Lawson GW, Rao NP, Crooks GM, Schiestl RH, Kasahara N. Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow. Exp Hematol. 2012 Jan;40(1):3-13.e3. Epub 2011 Oct 12

Logg CR, Robbins JM, Jolly DJ, Gruber HE, Kasahara N. Retroviral replicating vectors in cancer. Methods Enzymol. 2012;507:199-228.

Kubo S, Haga K, Tamamoto A, Palmer DJ, Ng P, Okamura H, Kasahara N. Adenovirus-retrovirus hybrid vectors achieve highly enhanced tumor transduction and antitumor efficacy in vivo. Mol Ther. 2011 Jan;19(1):76-82. Epub 2010 Aug 31